AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, andMorphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.
October 18, 2018
· 5 min read